

SCIENTIFIC DIRECTOR

Dr. ANTONINO MUSOLINO

Head of the Breast Unit, University Hospital of Parma

MEETING VENUE

HOTEL NH PARMA

Viale Paolo Borsellino, 31

43122 Parma PR

SUBSCRIPTION is free after registration online from the website www.mitcongressi.it section:

BREAST CANCER: FROM MOLECULAR SIGNATURES TO CLINICAL ONCOLOGY

CME We required **5** credits CME for the following professionals:

Surgeon (specialty in: **Allergy & Immunology, Pathology-Anatomic & Clinical, General Surgery, Thoracic Surgery, Medical Genetics, Obstetrics & Gynecology, Oncology, Radiology-Diagnostic, Radiation Oncology**)

Pharmacist

Biologist

Obstetrician

Nurse

BREAST CANCER: FROM MOLECULAR SIGNATURES TO CLINICAL ONCOLOGY

HOTEL NH PARMA 21 GIUGNO 2019

SEGRETERIA ORGANIZZATIVA

MI&T srl Viale Carducci 50 - 40125 Bologna - Tel. 051 220427
segreteria@mitcongressi.it - www.mitcongressi.it

UNRESTRICTED GRANT BY
GOLD SPONSOR



SILVER SPONSOR



GOIRC TRAINING PROJECT



UNDER THE AUSPICES OF



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero-Universitaria di Parma



UNIVERSITÀ
DI PARMA

9.15 **Registration**
9.45 **Welcome and Introduction** Antonino Musolino

BASIC AND TRANSLATIONAL SESSION: HOMOLOGOUS RECOMBINATION REPAIR (HRR)-DEFICIENT BREAST CANCERS

Chairmen: Luca Malorni, Gabriele Zoppoli

10.00 **Targeting DNA Repair** Benedetta Pellegrino

10.20 Discussion

10.30 **Introduction to the 1st Lecture** Antonino Musolino

10.35 **Preclinical data and translational relevance of Homologous Recombination Deficiency (HRD) in breast cancer** Violeta Serra

11.10 Coffee break

11.40 **BRCA1/2 testing: therapeutic implications for breast cancer management** Daniela Boggiani

12.00 Discussion

12.10 **Introduction to the 2nd Lecture** Antonino Musolino

12.15 **Phenotypic heterogeneity and evolution in patients with luminal breast cancer** Luca Magnani

12.50 Lunch

CLINICAL SESSION: UPDATES AND CONTROVERSIES IN BREAST CANCER TREATMENT

Chairmen: Francesco Leonardi, Antonino Musolino

13.50 **Introduction to the 3rd Lecture** Daniele Zanoni

13.55 **Are we hitting a ceiling on our therapeutic effectiveness in HER2-positive early breast cancer?** John P. Crown

14.25 **TNBC breast cancer** Maria Vittoria Dieci

14.45 Discussion

15.00 Coffee break

15.30 **Luminal-like breast cancer** Barbara Pistilli

15.50 Discussion

16.00 **HER2-positive breast cancer** Filippo Montemurro

16.20 Discussion

16.30 **Closing remarks and acknowledgements**

FACULTY

Daniela Boggiani University Hospital of Parma

John P. Crown St Vincent's University Hospital, Dublin IRL

Maria Vittoria Dieci Veneto Institute of Oncology IOV - IRCCS, Padua

Francesco Leonardi University Hospital of Parma

Luca Magnani Imperial College, London UK

Luca Malorni Azienda USL Toscana Centro, Prato

Filippo Montemurro Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin

Antonino Musolino University Hospital of Parma

Benedetta Pellegrino University Hospital of Parma

Barbara Pistilli Gustave Roussy Cancer Centre, Paris F

Violeta Serra VHIO, Barcelona E

Daniele Zanoni University Hospital of Parma

Gabriele Zoppoli University of Genoa and San Martino Hospital - IRCCS, Genoa

